HEOR

News

NICE says Libtayo can be used for advanced cervical cancer

New NICE guidance means that around 90 UK women with cervical cancer should be eligible for treatment with Regeneron's Libtayo each year.

News

EFPIA report adds to pressures on EU drug pricing policy

Pharma trade body EFPIA says access to new medicines is worsening across Europe, as it makes the socioeconomic case for spending more on novel drugs.

News

Sanofi's type 1 diabetes-delaying drug cleared for NHS use

People with early type 1 diabetes in England and Wales will soon be able to access Sanofi's Tzield, which can delay the need for insulin injections.

News

AbbVie's migraine drug cleared for migraine attacks on NHS

AbbVie's Aquipta can now be commissioned by the NHS in England and Wales as an acute treatment for migraine, after a NICE decision.

News

AbbVie's ovarian cancer drug Elahere gets NHS green light

AbbVie's Elahere has become the first new NHS therapy in more than 20 years for resistant ovarian cancer, providing an alternative to chemotherapy.

News

NICE changes stance on Genmab's cervical cancer drug

After saying it couldn't recommend Genmab's cervical cancer therapy Tivdak for use by the NHS, reimbursement authority NICE has had a change of heart.

NICE says Libtayo can be used for advanced cervical cancer

EFPIA report adds to pressures on EU drug pricing policy

Sanofi's type 1 diabetes-delaying drug cleared for NHS use

AbbVie's migraine drug cleared for migraine attacks on NHS

AbbVie's ovarian cancer drug Elahere gets NHS green light

NICE changes stance on Genmab's cervical cancer drug

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

HEOR

Editor's Picks